학술논문
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
Document Type
Article
Author
Wagner, Michael J.; Hennessy, Cassandra; Beeghly, Alicia; French, Benjamin; Shah, Dimpy P.; Croessmann, Sarah; Vilar-Compte, Diana; Ruiz-Garcia, Erika; Ingham, Matthew; Schwartz, Gary K.; Painter, Corrie A.; Chugh, Rashmi; Fecher, Leslie; Park, Cathleen; Zamulko, Olga; Trent, Jonathan C.; Subbiah, Vivek; Khaki, Ali Raza; Tachiki, Lisa; Nakasone, Elizabeth S.
Source
Subject
*REPORTING of diseases
*COVID-19
*HEALTH outcome assessment
*RETROSPECTIVE studies
*RISK assessment
*CANCER patients
*ARTIFICIAL respiration
*HOSPITAL mortality
*HOSPITAL care
*SOCIODEMOGRAPHIC factors
*SARCOMA
*LONGITUDINAL method
*DISEASE complications
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Sarcomas are a group of cancers with differing clinical features, some of which require long courses of cytotoxic chemotherapy. Therefore, patients with sarcoma may be at high risk of developing severe COVID-19. The aim of our study was to describe risk factors and clinical outcomes for patients with sarcoma and COVID-19. We show that patients with sarcoma have high rates of complications from COVID-19. Risk factors for more severe COVID-19 included older age, poor performance status, and lung metastases. We also compared 30 day mortality rates to a matched cohort of patients with sarcoma without COVID-19 and found that patients with bone sarcoma may be at higher risk of death from COVID-19 than patients with other sarcoma subtypes. Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death. [ABSTRACT FROM AUTHOR]